MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Erlotinib (Tarceva ®)

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

Cancer. 2008 Jun 9. [Epub ahead of print] [Link] Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Dana‐Farber Cancer Institute, Boston, Massachusetts. Abstract Background: We conducted a phase 2, multicenter, open-label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who […]

Comments Off on Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

Journal of Clinical Oncology. 2007 Jul 15;110(2):420-31. [Link] Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. University of Arizona Cancer Center, Tucson, AZ, USA. Abstract Purpose:Malignant pleural mesothelioma (MPM) expresses high levels of epidermal growth factor receptor (EGFR), and preclinical studies have identified […]

Comments Off on Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

Biology and management of malignant pleural mesothelioma

European Journal of Cancer. 2006 Sep 19; [Epub ahead of print] [Link] Paolo A. Zucali1, a and Giuseppe Giacconea aDepartment of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands Received 18 July 2006;  accepted 19 July 2006.  Available online 20 September 2006. Abstract Malignant mesothelioma is an aggressive tumour, […]

Comments Off on Biology and management of malignant pleural mesothelioma